奥美拉唑治疗特发性肺纤维化咳嗽的随机双盲安慰剂对照先导试验
本研究为单中心、双盲、随机、安慰剂对照先导试验,在特发性肺纤维化(IPF)患者中评估奥美拉唑(20 mg 每日两次,共3个月)的可行性、安全性与咳嗽频率。校正基线后,奥美拉唑组治疗结束时咳嗽频率几何均值较安慰剂组低39.1%(95%CI 低66.0%至高9.3%)。奥美拉唑耐受性良好,不良事件两组相似,但奥美拉唑组下呼吸道感染略多,第一秒用力呼气容积与用力肺活量小幅下降。
要点
- IPF患者中奥美拉唑20 mg每日两次治疗3个月耐受性良好,不良事件谱与安慰剂相似。
- 校正基线后奥美拉唑组咳嗽频率几何均值较安慰剂低39.1%,但95%CI跨越无效线。
- 奥美拉唑组下呼吸道感染略多、FEV与FVC小幅下降,后续试验需纳入相关安全性评估。
核心结论
- 在IPF患者中开展质子泵抑制剂(PPI)治疗咳嗽的大型随机对照试验看来可行且合理,但需解决随机化障碍并纳入呼吸道感染与肺功能变化的安全性评估。
研究设计与样本
- 单中心、双盲、随机、安慰剂对照先导试验,评估奥美拉唑(20 mg 每日两次,共3个月)在IPF患者中的可行性与可接受性。
- 为获得上述样本共筛查280例患者,停止使用抗酸药相关的障碍是未招募的最大单一原因;招募速度平均为每月1.5例参与者。
主要发现
- 校正基线后,治疗结束时奥美拉唑组咳嗽频率几何均值较安慰剂组低39.1%(95%CI 低66.0%至高9.3%)。
- 奥美拉唑耐受性良好,不良事件谱两组相似。
- 奥美拉唑组下呼吸道感染略多,并伴有第一秒用力呼气容积与用力肺活量的小幅下降。
关键数值与推荐
- 奥美拉唑剂量为20 mg 每日两次,疗程3个月。
- 主要临床结局为咳嗽频率,主要目标为评估试验程序的可行性与可接受性。
- 校正基线后咳嗽频率几何均值组间差异为低39.1%(95%CI 低66.0%至高9.3%)。
临床怎么用
- 结果提示在IPF患者中开展PPI治疗咳嗽的大型随机对照试验可行,可为后续研究设计提供依据。
- 后续试验需针对随机化障碍(如停用抗酸药)制定应对措施。
- 后续试验应纳入下呼吸道感染与肺功能变化的安全性评估。
局限性
- 为单中心设计,招募速度平均每月1.5例参与者,存在招募障碍。
- 咳嗽频率疗效的95%CI跨越无效线,结果需大型试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cough is a common, disabling symptom of idiopathic pulmonary fibrosis (IPF), which may be exacerbated by acid reflux. Inhibiting gastric acid secretion could potentially reduce cough. This study aimed to determine the feasibility of a larger, multicentre trial of omeprazole for cough in IPF, to assess safety and to quantify cough. METHODS: Single-centre, double-blind, randomised, placebo-controlled pilot trial of the proton pump inhibitor (PPI) omeprazole (20 mg twice daily for 3 months) in patients with IPF. Primary objectives were to assess feasibility and acceptability of trial procedures. The primary clinical outcome was cough frequency. RESULTS: Forty-five participants were randomised (23 to omeprazole, 22 to placebo), with 40 (20 in each group) having cough monitoring before and after treatment. 280 patients were screened to yield these numbers, with barriers to discontinuing antacids the single biggest reason for non-recruitment. Recruitment averaged 1.5 participants per month. Geometric mean cough frequency at the end of treatment, adjusted for baseline, was 39.1% lower (95% CI 66.0% lower to 9.3% higher) in the omeprazole group compared with placebo. Omeprazole was well tolerated and adverse event profiles were similar in both groups, although there was a small excess of lower respiratory tract infection and a small fall in forced expiratory volume and forced vital capacity associated with omeprazole. CONCLUSIONS: A large randomised controlled trial of PPIs for cough in IPF appears feasible and justified but should address barriers to randomisation and incorporate safety assessments in relation to respiratory infection and changes in lung function.
引用
- Dutta P, Funston W, Mossop H, et al. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax. 2019. PMID: 30610155. doi:10.1136/thoraxjnl-2018-212102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。